HLA B Leader in Patients With Psoriatic Arthritis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: blood test.
- Who it may be relevant to
- Registry conditions: Psoriatic Arthritis, HLA b Leader, HLA B27. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule. Given this association, these diseases are classically regarded as disorders of adaptive immunity. In bone marrow donation, HLA-B exon 1 dimorphism (HLAB leader) is associated with risk of graft- versus-host disease, relapse and overall survival after unrelated hematopoietic cell transplantation (UHCT), haploidentical UHCT and cord transplantation. In the literature, there are no studies suggesting the involvement of the HLA B leader gene in MS and RPs. The main aim of this study is to compare the presence of the HLA B leader gene between a group of patients with psoriatic arthritis and a healthy group without inflammatory disease.
Interventions
- Biological blood test
Addition of an extra tube for blood tests (a single tube for genetic research), enabling phenotyping of the HLA B27 and HLA B leader genes.
Primary outcome measures
- prevalence of HLA B leader in both groups [Time frame: 1 year]
Secondary outcome measures (2)
- Prevalence of HLAB27 gene in both groups [Time frame: 1 year]
- prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism patient group [Time frame: 1 year]
Eligibility criteria
Inclusion criteria
- For the "Patient" group:
- Patient over 18 years of age
- Patient affiliated to a social security scheme
- Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie.
- For the "control" group:
- Individuals over 18 years of age
- Individual affiliated to a social security scheme
- Individual having agreed to participate in the study
- Individuals with no inflammatory or autoimmune diseases
Exclusion criteria
- Patient or control not understanding French
- Patient not included in the Amiens Picardie University Hospital's "Psoriatic Rheumatism" cohort, or control not included in the Amiens Picardie University Hospital's bone marrow donor cohort.
- Patient or control objecting to participation in the study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Basic science
Study locations
France · 1 center
- CHU Amiens Picardie — Amiens
Identifiers
NCT: NCT07718815 · PI2024_843_0115